Indaptus Therapeutics, Inc. SEC filings INDP
Indaptus Therapeutics, Inc. has 343 filings in SEC EDGAR's recent list, going back to Apr 20, 2021. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 25, 2026 | — |
| EFFECT | Filing | Jul 17, 2026 | — |
| EFFECT | Filing | Aug 20, 2025 | — |
| EFFECT | Filing | Aug 20, 2025 | — |
| CORRESP | Letter to the SEC | Aug 19, 2025 | — |
| CORRESP | Letter to the SEC | Aug 19, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2025 | — |
| D | Filing | Jun 20, 2025 | — |
| DRS | Filing | Mar 27, 2025 | — |
| EFFECT | Filing | Mar 13, 2025 | — |
| EFFECT | Filing | Feb 13, 2025 | — |
| CORRESP | Letter to the SEC | Feb 13, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 12, 2025 | — |
| EFFECT | Filing | Feb 11, 2025 | — |
| CORRESP | Letter to the SEC | Feb 11, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2025 | — |
| D | Filing | Jan 22, 2025 | — |
| EFFECT | Filing | Dec 31, 2024 | — |
| CORRESP | Letter to the SEC | Dec 30, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 30, 2024 | — |
| D | Filing | Dec 6, 2024 | — |
| D/A | Filing | Oct 4, 2024 | — |
| EFFECT | Filing | Sep 20, 2024 | — |
| CORRESP | Letter to the SEC | Sep 18, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2024 | — |
| D | Filing | Aug 22, 2024 | — |
| EFFECT | Filing | Dec 30, 2022 | — |
| CORRESP | Letter to the SEC | Dec 30, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2022 | — |
| EFFECT | Filing | Sep 9, 2022 | — |
| RW | Filing | Sep 9, 2022 | — |
| CORRESP | Letter to the SEC | Sep 7, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2022 | — |
| AW | Filing | May 27, 2022 | — |
| AW | Filing | Mar 25, 2022 | — |
| EFFECT | Filing | Mar 23, 2022 | — |
| EFFECT | Filing | Dec 1, 2021 | — |
| RW | Filing | Sep 30, 2021 | — |
| EFFECT | Filing | Sep 29, 2021 | — |
| CORRESP | Letter to the SEC | Sep 28, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2021 | — |
| D | Filing | Aug 5, 2021 | — |
| CERT | Filing | Aug 3, 2021 | — |
| 425 | Filing | Jul 29, 2021 | — |
| 425 | Filing | Jul 23, 2021 | — |
| 8-A12B | Filing | Jul 23, 2021 | — |
| 425 | Filing | Jul 16, 2021 | — |
| 425 | Filing | Jun 22, 2021 | — |
| EFFECT | Filing | May 14, 2021 | — |
| CORRESP | Letter to the SEC | May 13, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2021 | — |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INDP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1857044
- Former names
- Intec Parent Inc. (until Aug 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.